PF 04479745 structure
|
Common Name | PF 04479745 | ||
|---|---|---|---|---|
| CAS Number | 1065110-43-1 | Molecular Weight | 282.383 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 473.4±45.0 °C at 760 mmHg | |
| Molecular Formula | C17H22N4 | Melting Point | N/A | |
| MSDS | USA | Flash Point | 240.1±28.7 °C | |
Use of PF 04479745PF-4479745 is a potent and selective 5-HT2C receptor agonist (EC50: 10 nM, ki: 15 nM). PF-4479745 can be used in the research of cardiovascular disease like hypertension[1]. |
| Name | PF-4479745 |
|---|---|
| Synonym | More Synonyms |
| Description | PF-4479745 is a potent and selective 5-HT2C receptor agonist (EC50: 10 nM, ki: 15 nM). PF-4479745 can be used in the research of cardiovascular disease like hypertension[1]. |
|---|---|
| Related Catalog | |
| Target |
5-HT2C Receptor:10 nM (EC50) 5-HT2C Receptor:15 nM (Ki) 5-HT2A Receptor:360 nM (IC50) 5-HT2B Receptor:67 nM (IC50) 5-HT1A Receptor:500 nM (IC50) 5-HT6 Receptor:280 nM (IC50) |
| In Vitro | PF-4479745 (copmpound 17) exhibits metabolic stability in both human liver microsomes (HLM) and human hepatocytes[1]. |
| In Vivo | PF-4479745 (compound 17, intravenous injection) shows high clearance rate (104 mL/min/kg)[1]. PF-4479745 demonstrates a robust dose-dependent effect in canine PUP (peak urethral pressure) model of SUI (stress urinary incontinence)[1]. |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 473.4±45.0 °C at 760 mmHg |
| Molecular Formula | C17H22N4 |
| Molecular Weight | 282.383 |
| Flash Point | 240.1±28.7 °C |
| Exact Mass | 282.184448 |
| LogP | 2.68 |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
| Index of Refraction | 1.590 |
| RIDADR | NONH for all modes of transport |
|---|
| MFCD28137682 |
| PF-04479745 |
| 5H-Pyrimido[4,5-d]azepin-4-amine, 6,7,8,9-tetrahydro-N,9-dimethyl-2-(phenylmethyl)-, (9S)- |
| (9S)-2-Benzyl-N,9-dimethyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine |
| (9S)-6,7,8,9-Tetrahydro-N,9-dimethyl-2-(phenylmethyl)-5H-pyrimido[4,5-d]azepin-4-amine |
| PF-4479745 |